Vitiligo

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

Retrieved on: 
Monday, April 1, 2024
Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Research, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.

Key Points: 
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Herve Hoppenot, Chief Executive Officer, Incyte.
  • Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline ILUMETRI (tildrakizumab injection), original drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.”
    The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

Retrieved on: 
Thursday, March 28, 2024
Dermatology, Vitiligo, Growth, Science, History, Female, American Academy, Light, Skin, Melanocortin, Depigmentation, Peptide

DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.

Key Points: 
  • DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.
  • Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf.
  • CLINUVEL is now investing heavily in R&D with an ambitious clinical pipeline, including a phase III clinical trial for the pigment loss disorder vitiligo.
  • “German investors have been pivotal in supporting our work thus far and we hope to share our success with the wider investment community.”

AMERICAN SKIN ASSOCIATION SPRING GALA CELEBRATES OUTSTANDING HONOREES

Retrieved on: 
Friday, April 5, 2024
Eli Lilly, Organization, Master of ceremonies, Psoriasis, Vitiligo, Atopic dermatitis, Skin cancer, NBC, Patient, Research, Pioneer, Hope, Doctor of Philosophy, MD, Student, Inauguration, SPOTS, ASA, Skin, Melanoma, Eli Lilly and Company, Plaza Hotel, Physician, Pharmaceutical industry

NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala. They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health. The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.

Key Points: 
  • Gala honors Pioneer in Dermatology, Emma Guttman-Yassky, MD, PhD and Global Pharmaceutical Leader Eli Lilly and Company
    NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala.
  • They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health.
  • The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.
  • Recipients, who work on breakthrough efforts to prevent, detect, and treat skin cancer and other skin diseases, have gone on to become top researchers in dermatology.

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Retrieved on: 
Monday, April 1, 2024
Research, Biotechnology, Other Health, Health, Cosmetics, Pharmaceutical, Retail, Science, Oncology, Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Key Points: 
  • Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

JDRF Shines Light on Type 1 Diabetes During Autoimmune Awareness Month

Retrieved on: 
Tuesday, March 26, 2024
Community, Diagnosis, Research, Health, Vitiligo, Disease, Partnership, Insulin, Risk, T1D, Autoantibody, Pancreas, JDRF, Immune system, FDA, Clinical trial, Autoimmune disease, Pharmaceutical industry

NEW YORK, March 26, 2024 /PRNewswire/ -- In recognition of Autoimmune Awareness Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes all those who live with T1D, an autoimmune condition that causes the pancreas to make very little insulin or none at all. T1D is one of nearly 100 autoimmune diseases that occur when the body's immune system mistakenly attacks another part of the body. While there are currently no cures for autoimmune diseases, screening options may be available, which can reduce the risk of life-threatening complications at diagnosis and provide people time to develop a plan in partnership with their healthcare team. JDRF continues advancing breakthroughs to find cures for T1D, including research that has the potential to impact other autoimmune diseases.

Key Points: 
  • Screening for type 1 diabetes can reduce the risk of life-threatening complications at diagnosis.
  • NEW YORK, March 26, 2024 /PRNewswire/ -- In recognition of Autoimmune Awareness Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes all those who live with T1D, an autoimmune condition that causes the pancreas to make very little insulin or none at all.
  • JDRF continues advancing breakthroughs to find cures for T1D, including research that has the potential to impact other autoimmune diseases.
  • JDRF encourages those with T1D and other autoimmune diseases to share their stories and continue to build awareness of their conditions and opportunities for screening.

THE DERMATOLOGY FOUNDATION AND SKIN OF COLOR SOCIETY BESTOW THE FIRST-EVER SANOFI AND REGENERON DIVERSITY, EQUITY, AND INCLUSION MID-CAREER AWARD ON DONALD A. GLASS II, MD, PhD, FAAD

Retrieved on: 
Tuesday, March 19, 2024
SOCS, Autoimmunity, University, Glass, Regeneron Pharmaceuticals, Associate, Health equity, Genetics, Patient, DF, Research, Diversity, American Academy, Doctor of Philosophy, MBA, Skin, University of Massachusetts, MPH, Comorbidity, FAAD, Bangladesh Technical Education Board, DEI, Vitiligo, Medicine, Pharmaceutical industry

CHICAGO, March 19, 2024 /PRNewswire/ -- The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Donald A. Glass II, MD, PhD, FAAD, is the 2024 recipient of the first-ever Sanofi and Regeneron Diversity, Equity, and Inclusion (DEI) Mid-Career Award, given to support his research into "Genetics, Comorbidities and their Association with Keloids."

Key Points: 
  • A nationally recognized keloids expert, Dr. Glass is an Associate Professor at the University of Texas Southwestern Medical Center in Dallas, Texas.
  • He served as 2021-2022 President of the Skin of Color Society.
  • The Sanofi and Regeneron DEI Mid-Career Award was developed especially for the exceptional mid-career investigator with an established trajectory of excellence in basic, clinical or translational science.
  • Our sincere congratulations to Dr. Glass, the outstanding first award recipient for this highly competitive award—and our sincere gratitude to Sanofi and Regeneron for making the award possible."

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

Retrieved on: 
Thursday, March 7, 2024
Lichen planus, Light therapy, Assistant, Vitiligo, Marketing, Cutaneous T-cell lymphoma, Quality of life, Senate, Atopic dermatitis, Skin, CTCL, Mycosis fungoides, CPT, Human, Light, Alopecia areata, Patient, STRATA, SSKN, Insurance, Pharmaceutical industry

The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

Key Points: 
  • The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.
  • “Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA.
  • Over the past two months, as part of this advocacy initiative STRATA has sent over 1,000 legislative support letters to congressional and senate delegates on behalf of its patients.
  • Phototherapy has been the cornerstone of therapy for decades and remains an indispensable part of current therapy.

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024
Skin cancer, EPP, Pigment, Nervous system, Attacca Quartet, Growth, XP, Skin, Xeroderma pigmentosum, Global health, Life, Parker, Risk, Health, Vitiligo, Peptide, Melanocortin, Patient, Medicine, Knowledge, Research, Brain, Pharmaceutical industry

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Investigational New Drug, Psoriasis, FDA, Food, Conference, Vitiligo, Biomarker, Therapy, Patient, Drug discovery, IND, BET, Pharmaceutical industry

“We have made excellent progress with our VYN201 program and remain on track to initiate a Phase 2b trial in nonsegmental vitiligo next quarter.

Key Points: 
  • “We have made excellent progress with our VYN201 program and remain on track to initiate a Phase 2b trial in nonsegmental vitiligo next quarter.
  • Trial startup activities are ongoing with patient enrollment expected to begin in the second quarter of 2024.
  • VYNE recently completed this study and achieved preliminary results consistent with its expectations at the outset of the study.
  • VYNE plans to submit the requested nonclinical information to the FDA by the end of the first quarter of 2024.

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Retrieved on: 
Tuesday, February 27, 2024
Vitiligo, Therapy, BET, Topical medication, Pharmaceutical industry

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201

Key Points: 
  • Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201
    BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentation featuring positive data from the Phase 1b trial of VYN201 in vitiligo at the 2024 Global Vitiligo Foundation Annual Scientific Symposium taking place in San Diego on March 7, 2024.
  • “We are pleased to have this opportunity to present the data from our Phase 1b trial with the vitiligo community at the Global Vitiligo Foundation Annual Scientific Symposium,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE.
  • “The positive clinical data from the Phase 1b trial supports the advancement of VYN201 into a Phase 2b trial that we expect to initiate next quarter.”
    A Phase 1 Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of a Topical Pan-BD BET Inhibitor (VYN201) in Subjects with Active Non-Segmental Vitiligo (session #4)